Levetiracetam Inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture

Neuroscience Letters

Volumn 436, Issue 3, 2008, Pages 289-293

  Nagarkatti, Nisha ^a,b   Deshpande, Laxmikant S ^a   DeLorenzo, Robert J ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hippocampal culture; Inositol 1,4,5 Trisphosphate; Levetiracetam; Ryanodine

Indexed keywords

BRADYKININ; CAFFEINE; CALCIUM; ETIRACETAM; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; ANIMALS, NEWBORN; BRADYKININ; CAFFEINE; CALCIUM; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIPPOCAMPUS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; NEURONS; NOOTROPIC AGENTS; PHOSPHODIESTERASE INHIBITORS; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 43049148382     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.02.076     Document Type: Article

References (40)

1. Angehagen M., Margineanu D.G., Ben-Menachem E., Ronnback L., Hansson E., and Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 14 (2003) 471-475
2. Annegers J.F., Rocca W.A., and Hauser W.A. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin. Proc. 71 (1996) 570-575
3. Berridge M.J. Neuronal calcium signaling. Neuron 21 (1998) 13-26
4. Cataldi M., Lariccia V., Secondo A., di Renzo G., and Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J. Pharmacol. Exp. Ther. 313 (2005) 720-730
5. Choi D.W. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. 58 (1985) 293-297
6. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7 (1987) 369-379
7. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15268-15273
8. Custer K.L., Austin N.S., Sullivan J.M., and Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26 (2006) 1303-1313
9. De Smedt T., Raedt R., Vonck K., and Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 13 (2007) 43-56
10. Delorenzo R.J., Sun D.A., and Deshpande L.S. Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. Pharmacol. Ther. 105 (2005) 229-266
11. Desaulles E., Boux O., and Feltz P. Caffeine-induced Ca2+ release inhibits GABAA responsiveness in rat identified native primary afferents. Eur. J. Pharmacol. 203 (1991) 137-140
12. Freund T.F., Ylinen A., Miettinen R., Pitkanen A., Lahtinen H., Baimbridge K.G., and Riekkinen P.J. Pattern of neuronal death in the rat hippocampus after status epilepticus. Relationship to calcium binding protein content and ischemic vulnerability. Brain Res.. Bull. 28 (1992) 27-38
13. Greene R.W., Haas H.L., and Hermann A. Effects of caffeine on hippocampal pyramidal cells in vitro. Br. J. Pharmacol. 85 (1985) 163-169
14. Hauser W.A., Annegers J.F., and Rocca W.A. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. 71 (1996) 576-586
15. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology (2007)
16. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 Suppl. 4 (2001) 13-18
17. Klitgaard H., and Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 5 Suppl. 1 (2003) S9-S16
18. Koulen P., and Thrower E.C. Pharmacological modulation of intracellular Ca(2+) channels at the single-channel level. Mol. Neurobiol. 24 (2001) 65-86
19. Limbrick Jr. D.D., Churn S.B., Sombati S., and DeLorenzo R.J. Inability to restore resting intracellular calcium levels as an early indicator of delayed neuronal cell death. Brain Res. 690 (1995) 145-156
20. Limbrick Jr. D.D., Pal S., and DeLorenzo R.J. Hippocampal neurons exhibit both persistent Ca2+ influx and impairment of Ca2+ sequestration/extrusion mechanisms following excitotoxic glutamate exposure. Brain Res. 894 (2001) 56-67
21. Lowenstein D.H., Thomas M.J., Smith D.H., and McIntosh T.K. Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus. J. Neurosci. 12 (1992) 4846-4853
22. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
23. Margineanu D.G., and Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur. J. Pharmacol. 466 (2003) 255-261
24. McPherson P.S., Kim Y.K., Valdivia H., Knudson C.M., Takekura H., Franzini-Armstrong C., Coronado R., and Campbell K.P. The brain ryanodine receptor: a caffeine-sensitive calcium release channel. Neuron 7 (1991) 17-25
25. Mody I., and MacDonald J.F. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol. Sci. 16 (1995) 356-359
26. Mori F., Okada M., Tomiyama M., Kaneko S., and Wakabayashi K. Effects of ryanodine receptor activation on neurotransmitter release and neuronal cell death following kainic acid-induced status epilepticus. Epilepsy Res. 65 (2005) 59-70
27. Noyer M., Gillard M., Matagne A., Henichart J.P., and Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
28. Osugi T., Uchida S., Imaizumi T., and Yoshida H. Bradykinin-induced intracellular Ca2+ elevation in neuroblastoma X glioma hybrid NG108-15 cells; relationship to the action of inositol phospholipids metabolites. Brain Res. 379 (1986) 84-89
29. Pal S., Sun D., Limbrick D., Rafiq A., and DeLorenzo R.J. Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. Cell Calcium 30 (2001) 285-296
30. Palma E., Ragozzino D., Di Angelantonio S., Mascia A., Maiolino F., Manfredi M., Cantore G., Esposito V., Di Gennaro G., Quarato P., Miledi R., and Eusebi F. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 48 (2007) 1842-1849
31. Raza M., Blair R.E., Sombati S., Carter D.S., Deshpande L.S., and DeLorenzo R.J. Evidence that injury-induced changes in hippocampal neuronal calcium dynamics during epileptogenesis cause acquired epilepsy. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17522-17527
32. Sirsi D., and Safdieh J.E. The safety of levetiracetam. Expert Opin. Drug Saf. 6 (2007) 241-250
33. Sombati S., and Delorenzo R.J. Recurrent spontaneous seizure activity in hippocampal neuronal networks in culture. J. Neurophysiol. 73 (1995) 1706-1711
34. Tong X., and Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br. J. Pharmacol. 133 (2001) 867-874
35. Uneyama H., Munakata M., and Akaike N. Caffeine response in pyramidal neurons freshly dissociated from rat hippocampus. Brain Res. 604 (1993) 24-31
36. Usachev Y., Shmigol A., Pronchuk N., Kostyuk P., and Verkhratsky A. Caffeine-induced calcium release from internal stores in cultured rat sensory neurons. Neuroscience 57 (1993) 845-859
37. Wang H., Gao J., Lassiter T.F., McDonagh D.L., Sheng H., Warner D.S., Lynch J.R., and Laskowitz D.T. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit. Care 5 (2006) 71-78
38. Willmore L.J. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav. 7 Suppl. 3 (2005) S25-S28
39. Xu T., and Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell Biol. 3 (2001) 691-698
40. Zona C., Niespodziany I., Marchetti C., Klitgaard H., Bernardi G., and Margineanu D.G. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 10 (2001) 279-286